Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
100 hedge funds and large institutions have $506M invested in Astria Therapeutics in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 39 increasing their positions, 27 reducing their positions, and 25 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 27
8% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 25
2% less funds holding
Funds holding: 102 → 100 (-2)
3.76% less ownership
Funds ownership: 104.98% → 101.22% (-3.8%)
38% less capital invested
Capital invested by funds: $811M → $506M (-$305M)
63% less call options, than puts
Call options by funds: $215K | Put options by funds: $577K
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$21M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.9M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$6.59M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$6.16M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$5.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$24.6M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$18.3M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$13.8M |
| 4 |
AG
Artal Group
Luxembourg
|
-$12.4M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.63M |
ATXS Hedge Fund Activity: Q2 2024 in Review
100 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q2 2024, worth a combined $506M — down 38% from $811M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ATXS and 23 opened new positions — a net loss of 2 holders — while 27 trimmed existing stakes and 39 added.
The largest buyer was Vestal Point Capital, adding an estimated $21M. The largest seller was TCG Crossover Management, cutting an estimated $24.6M.
- 100 institutional investors held Astria Therapeutics (ATXS) as of Q2 2024, down from 102 in Q1 2024.
- Funds reported $506M of Astria Therapeutics stock for Q2 2024, down 38% quarter-over-quarter.
- 23 funds opened new Astria Therapeutics positions in Q2 2024 and 25 closed out, a net change of -2 holders.
- The largest Astria Therapeutics buyer in Q2 2024 was Vestal Point Capital, an estimated $21M added.
- The largest Astria Therapeutics seller in Q2 2024 was TCG Crossover Management, an estimated $24.6M sold.
Based on aggregated 13F filings for Q2 2024.